Form 4: Kymera Director Sells Shares After Option Exercise

Kymera Therapeutics Director Pamela Esposito exercised stock options and subsequently sold all acquired shares under a pre-arranged 10b5-1 trading plan.

Summary

• Pamela Esposito, a Director at Kymera Therapeutics, Inc., engaged in transactions involving the company's common stock on March 20, 2026.
• Esposito exercised stock options to acquire 2,500 shares of common stock at an exercise price of $49.1 per share.
• Immediately following the option exercise, Esposito sold all 2,500 shares in three separate transactions.
• The sales occurred at weighted average prices of $77.7111 (700 shares), $79.2439 (600 shares), and $79.9442 (1,200 shares).
• All transactions were conducted under a Rule 10b5-1 trading plan established on September 17, 2025.
• Following these transactions, Esposito's direct beneficial ownership of Kymera Therapeutics common stock is 0 shares.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a routine, pre-planned insider transaction for diversification and compensation realization, rather than a signal of negative company performance. The profit from the sale is positive for the individual.

Positives

• The transactions were executed under a pre-arranged Rule 10b5-1 trading plan, indicating a planned sale rather than a reaction to new negative information.
• The sale prices ($77.71 to $79.94) are significantly higher than the exercise price ($49.1), indicating a profitable transaction for the director.

Negatives

• A director selling all their directly owned shares, even if pre-planned, could be perceived negatively by some investors as it reduces their direct equity stake in the company.

Future Outlook

No future outlook or guidance is provided in this Form 4 filing, as it primarily reports past insider transactions.

Industry Context

StockSavvy.ai notes that insider sales, even under 10b5-1 plans, are common for compensation and diversification purposes, particularly in the biotechnology sector where executive compensation often includes significant equity components. These transactions do not typically signal a change in company fundamentals unless they are large, unscheduled, or involve a significant portion of the insider's holdings without a clear pre-planned structure.

Comparison to Industry Standards

• Insider transactions under Rule 10b5-1 plans are a standard practice for executives and directors to manage their equity holdings and diversify their portfolios while complying with insider trading regulations.
• Many biotech executives, similar to those at companies like Moderna (MRNA) or BioNTech (BNTX), utilize such plans to systematically monetize vested equity compensation.
• The profit realized from the option exercise and sale reflects the appreciation of Kymera's stock price above the option's strike price, a common outcome for long-term equity incentives.

Stakeholder Impact

• Shareholders: The sale by a director could be interpreted in various ways, but given the 10b5-1 plan, it's generally seen as a planned financial move rather than a loss of confidence. The reduction in direct ownership might be a minor concern for some.

Key Dates

Recommendation

The filing details a pre-planned insider sale, which is a common occurrence for executives managing their personal portfolios. It does not provide new information about the company's operational performance or future prospects that would warrant a change in investment thesis. The transactions were profitable for the director, reflecting past stock appreciation.

Keywords

Kymera Therapeutics, KYMR, Form 4, Insider Trading, Stock Option Exercise, Share Sale, Pamela Esposito, 10b5-1 Plan, Director Transactions